Sirtex and Guerbet team for liver cancer studies
25 March, 2014 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has signed an agreement to evaluate using its SIR-Spheres microspheres in conjunction with Guerbet's Lipidol to treat a range of liver cancers.
Patrys preps for clinical trials of PAT-LM1
24 March, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) is gearing up to take its second anticancer antibody, PAT-LM1, to the clinic after the candidate showed promise in leukaemias and lymphomas.
Ascend cancer drug shows potential in CBCL
21 March, 2014 by Dylan Bushell-EmblingMore than 80% of patients with cutaneous B-cell lymphoma enrolled in a phase II trial of Ascend's in-licensed cancer drug ASN-002 demonstrated a complete or partial response to treatment.
STA gets TGA nod for Abraxane in pancreatic cancer
19 March, 2014 by Dylan Bushell-EmblingThe TGA has approved the use of Abraxane - a cancer drug licensed by Specialised Therapeutics Australia - in first-line treatment of metastatic pancreatic cancer.
Virax to buy Pathway Oncology
19 March, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has arranged to buy Pathway Oncology, a company with an exclusive licence to a cancer drug candidate due to enter phase II trials in breast cancer and multiple myeloma.
Link between diabetes and pancreatic cancer
19 March, 2014A systematic review of independent studies has found an association between pancreatic cancer and diabetes.
Bionomics' renal cancer trial finds key subgroups
19 March, 2014 by Dylan Bushell-EmblingBionomics (ASX:BNO) has revealed that its BNC105 candidate improved PFS in subgroups of patients with advanced renal cancer during a phase II trial.
Biomedical Research Victoria
18 March, 2014Melbourne's Bio21 Cluster has transitioned into Biomedical Research Victoria, a new statewide biomedical research group.
Imugene kicks off IND process for HER-Vaxx
18 March, 2014 by Dylan Bushell-EmblingImugene (ASX:IMU) has appointed Ground Zero Pharmaceuticals to help the company prepare its Investigational New Drug application with the US FDA for cancer vaccine HER-Vaxx.
Starpharma's VivaGel condoms approved in Japan
17 March, 2014 by Dylan Bushell-EmblingStarpharma's (ASX:SPL) marketing partner Okamoto Industries has won regulatory approval to market VivaGel-coated condoms in Japan.
Calzada appoints new chairman
17 March, 2014 by Dylan Bushell-EmblingCalzada's (ASX:CZD) newest director, David Williams, has been chosen to replace Roger Aston as board chairman.
Viralytics closes $27m capital raising
14 March, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) said a recent $27.1m placement and entitlement offer has left it with enough cash to fund its cancer trial programs through 2016.
Bionomics, CEO win industry awards
13 March, 2014 by Dylan Bushell-EmblingBionomics (ASX:BNO) has been named Innovative Asian Biotech of the Year, and CEO Deborah Rathjen Life Science Woman Executive of the Year, at the BioPharma Asia Industry Awards.
GTG breast cancer test found to be cost-effective
12 March, 2014 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) said economic modelling has shown the cost-effectiveness of using BREVAGen to help direct chemoprevention to women at elevated risk of breast cancer.
Starpharma gets $4.7m R&D tax incentive
11 March, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has been allocated its $4.7m R&D tax incentive rebate on its FY13 expenditures, and revealed it ended 1H14 in a cash position of $27.8m.
